Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 15/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18953768 | 0.89 | ELANE (0.45) | ELANEF2PLAULMNAGABRG2 | |
| SCHEMBL17023332 | 0.83 | ELANE (0.39) | ELANEF2PLAU | |
| SCHEMBL793283 | 0.82 | ELANE (0.55) | ELANEF2PLAU | |
| SCHEMBL29868622 | 0.81 | KDM4E (0.41) | GABRG2GABRB3GABRA5 | |
| SCHEMBL24247769 | 0.80 | ELANE (0.55) | ELANEF2PLAUMAPTLMNA | |
| SCHEMBL18953725 | 0.80 | ELANE (0.53) | ELANEF2PLAUMAPTLMNA | |
| SCHEMBL19208509 | 0.80 | TSHR (0.42) | ELANE | |
| SCHEMBL31559870 | 0.79 | FPR2 (0.38) | MAPTLMNA | |
| SCHEMBL9959858 | 0.78 | ELANE (0.57) | ELANEF2PLAUMAPTLMNA | |
| SCHEMBL18549431 | 0.77 | ELANE (0.39) | ELANEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10301336-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190085005-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10100072-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-10000516-B2 | Phosphonate compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | US | disclosed |
| US-9663543-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663543-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663543-B2 | Phosphonate compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| WO-2017035357-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| WO-2015130845-A9 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2015130845-A9 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2015130845-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015130845-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362432-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | ELANE 230/4885F2 20/4885PLAU 835/4885 |
| US-10100072-B2 | Phosphonate compounds for treatment of complement mediated disorders | CFD, TFPI, C1QBP | ELANE 420/4885F2 26/4885PLAU 684/4885 |
| US-10301336-B2 | Phosphonate compounds for treatment of complement mediated disorders | CFD, TFPI, C1QBP | ELANE 420/4885F2 26/4885PLAU 684/4885 |
| US-20170260219-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | ELANE 420/4885F2 26/4885PLAU 684/4885 |
| US-20190085005-A1 | PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, TFPI, C1QBP | ELANE 420/4885F2 26/4885PLAU 684/4885 |
| US-20150239921-A1 | Phosphonate Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C1QBP | ELANE 420/4885F2 26/4885PLAU 684/4885 |
| US-10000516-B2 | Phosphonate compounds for treatment of medical disorders | CFD, TFPI, CFH | ELANE 336/4885F2 16/4885PLAU 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.